Pharmaceutical and Healthcare Industry in Russia - Forecast and Analysis 2021
The Russian healthcare system is primarily funded by the federal government, though the industry is making a significant shift towards private healthcare spending in recent years. The country has made considerable progress in managing the COVID-19 pandemic and even released the first-ever vaccine to protect its population against the novel coronavirus infection. However, the number of new infections and deaths from COVID-19 still continues. The country is hoping for a rapid vaccination program for its adult population.
There is no denying that the Russian pharmaceutical sector is one of the biggest in the CEE market and globally as well. The Russian economy has been facing a period of recession in recent years. The COVID-19 situation is also expected to negatively impact the healthcare and pharmaceutical sectors further. At the same time, there remains a vast difference between the rich and poor population and their access to healthcare.
While several domestic players are active in the industry, the pharmaceutical industry in Russia is primarily dominated by foreign companies like Sanofi, Johnson & Johnson, AstraZeneca, and many others. Local companies that are active in the sector include Veropharm, Pharmstandard, and Pharmsynthez.
Aruvian Research presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of Russia in its research report Pharmaceutical and Healthcare Industry in Russia – Forecast and Analysis 2021. The report covers the following data:
There is no denying that the Russian pharmaceutical sector is one of the biggest in the CEE market and globally as well. The Russian economy has been facing a period of recession in recent years. The COVID-19 situation is also expected to negatively impact the healthcare and pharmaceutical sectors further. At the same time, there remains a vast difference between the rich and poor population and their access to healthcare.
While several domestic players are active in the industry, the pharmaceutical industry in Russia is primarily dominated by foreign companies like Sanofi, Johnson & Johnson, AstraZeneca, and many others. Local companies that are active in the sector include Veropharm, Pharmstandard, and Pharmsynthez.
Aruvian Research presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of Russia in its research report Pharmaceutical and Healthcare Industry in Russia – Forecast and Analysis 2021. The report covers the following data:
- An in-depth coverage of the pharmaceutical and healthcare industry in Russia by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
- We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for medical research and clinical trials in Russia.
- A SWOT analysis of the Russian pharmaceutical and healthcare industry.
- A Porter's Five Forces Strategic Analysis of the Russian pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.
- We take an up-close view of the regulatory framework governing the Russian pharmaceutical and healthcare industry, and the challenges being faced in terms of intellectual property rights.
- Competition in the industry, along with an in-depth analysis of the both the domestic and multinational players in the sector like Pharmstandard OJSC, Veropharm, AstraZeneca, Johnson & Johnson, Novartis, and many others are included.
A. EXECUTIVE SUMMARY
B. INDUSTRY DEFINITION
C. BRIEF VIEW OF THE CEE PHARMACEUTICAL & HEALTHCARE SECTOR
D. PHARMACEUTICAL & HEALTHCARE INDUSTRY IN RUSSIA
D.1 Impact of COVID-19 on the Industry
D.2 Pharmaceutical Sector Analysis
D.3 Healthcare Sector Analysis
D.4 Telemedicine in Russia
D.5 Market for Prescription Drugs
D.6 Market for Patented Drugs
D.7 Market for OTC Medicines
D.8 Market for Generic Drugs
D.9 Medical Research & Clinical Trials in Russia
E. PHARMACEUTICAL & HEALTHCARE INDUSTRY IN RUSSIA: SWOT ANALYSIS
E.1 Strengths to Build Upon
E.2 Weaknesses to Overcome
E.3 Opportunities to Exploit
E.4 Threats to Overcome
F. RUSSIA PHARMACEUTICAL INDUSTRY: PORTER’S FIVE FORCES STRATEGY ANALYSIS
F.1 Overview
F.2 Bargaining Power of Buyers
F.3 Bargaining Power of Suppliers
F.4 Competitive Rivalry in the Industry
F.5 Threat of New Entrants
F.6 Threat of Substitutes
G. CHRONIC MEDICAL CONDITIONS IN RUSSIA
G.1 Overview
G.2 Cancer
G.3 Cardiovascular Disease
G.4 HIV/AIDS
H. REGULATORY FRAMEWORK OF THE INDUSTRY
H.1 Overview
H.2 Putin’s Pharma 2020 Plan
H.3 Challenges with Intellectual Property Rights
H.4 Pricing & Reimbursement Regime
H.5 Regulatory & Other Challenges
I. IMPORT/EXPORT OF PHARMACEUTICALS
J. COMPETITION IN THE INDUSTRY
J.1 Competitive Landscape
J.2 Competition in Generic Drugs
J.3 Competition in the Pharmacy Sector
J.4 Competition in Drug Distribution
K. FORECAST: PHARMACEUTICAL & HEALTHCARE INDUSTRY IN RUSSIA
K.1 Outlook of the Russian Pharmaceutical Industry
K.2 Outlook of the Russian Healthcare Industry
K.3 Outlook for Prescription Drugs Sector
K.4 Outlook for Patented Drugs Market
K.5 Outlook for OTC Medicine Market
K.6 Outlook for the Generic Drugs Market
L. MAJOR DOMESTIC & MULTINATIONAL PLAYERS
L.1 Pharmstandard OJSC
##L.1.1 Corporate Analysis
##L.1.2 Business Segment Analysis
##L.1.3 Financial Analysis
##L.1.4 SWOT Analysis
L.2 Veropharm
##L.2.1 Corporate Analysis
##L.2.2 Business Segment Analysis
##L.2.3 Financial Analysis
##L.2.4 SWOT Analysis
L.3 AbbVie
##L.3.1 Corporate Analysis
##L.3.2 Business Segment Analysis
##L.3.3 Financial Analysis
##L.3.4 SWOT Analysis
L.4 AstraZeneca
##L.4.1 Corporate Analysis
##L.4.2 Business Segment Analysis
##L.4.3 Financial Analysis
##L.4.4 SWOT Analysis
L.5 GlaxoSmithKline
##L.5.1 Corporate Analysis
##L.5.2 Business Segment Analysis
##L.5.3 Financial Analysis
##L.5.4 SWOT Analysis
L.6 Johnson & Johnson
##L.6.1 Corporate Analysis
##L.6.2 Business Segment Analysis
##L.6.3 Financial Analysis
##L.6.4 SWOT Analysis
L.7 Merck & Co.
##L.7.1 Corporate Analysis
##L.7.2 Business Segment Analysis
##L.7.3 Financial Analysis
##L.7.4 SWOT Analysis
L.8 Novartis
##L.8.1 Corporate Analysis
##L.8.2 Business Segment Analysis
##L.8.3 Financial Analysis
##L.8.4 SWOT Analysis
L.9 Pfizer
##L.9.1 Corporate Analysis
##L.9.2 Business Segment Analysis
##L.9.3 Financial Analysis
##L.9.4 SWOT Analysis
L.10 Sanofi SA
##L.10.1 Corporate Analysis
##L.10.2 Business Segment Analysis
##L.10.3 Financial Analysis
##L.10.4 SWOT Analysis
L.11 Takeda Pharmaceutical
##L.11.1 Corporate Analysis
##L.11.2 Business Segment Analysis
##L.11.3 Financial Analysis
##L.11.4 SWOT Analysis
L.12 Biocad
L.13 Pharmsynthez
L.14 R-Pharm
M. GLOSSARY OF TERMS
N. RESEARCH METHODOLOGY
O. DISCLAIMER
B. INDUSTRY DEFINITION
C. BRIEF VIEW OF THE CEE PHARMACEUTICAL & HEALTHCARE SECTOR
D. PHARMACEUTICAL & HEALTHCARE INDUSTRY IN RUSSIA
D.1 Impact of COVID-19 on the Industry
D.2 Pharmaceutical Sector Analysis
D.3 Healthcare Sector Analysis
D.4 Telemedicine in Russia
D.5 Market for Prescription Drugs
D.6 Market for Patented Drugs
D.7 Market for OTC Medicines
D.8 Market for Generic Drugs
D.9 Medical Research & Clinical Trials in Russia
E. PHARMACEUTICAL & HEALTHCARE INDUSTRY IN RUSSIA: SWOT ANALYSIS
E.1 Strengths to Build Upon
E.2 Weaknesses to Overcome
E.3 Opportunities to Exploit
E.4 Threats to Overcome
F. RUSSIA PHARMACEUTICAL INDUSTRY: PORTER’S FIVE FORCES STRATEGY ANALYSIS
F.1 Overview
F.2 Bargaining Power of Buyers
F.3 Bargaining Power of Suppliers
F.4 Competitive Rivalry in the Industry
F.5 Threat of New Entrants
F.6 Threat of Substitutes
G. CHRONIC MEDICAL CONDITIONS IN RUSSIA
G.1 Overview
G.2 Cancer
G.3 Cardiovascular Disease
G.4 HIV/AIDS
H. REGULATORY FRAMEWORK OF THE INDUSTRY
H.1 Overview
H.2 Putin’s Pharma 2020 Plan
H.3 Challenges with Intellectual Property Rights
H.4 Pricing & Reimbursement Regime
H.5 Regulatory & Other Challenges
I. IMPORT/EXPORT OF PHARMACEUTICALS
J. COMPETITION IN THE INDUSTRY
J.1 Competitive Landscape
J.2 Competition in Generic Drugs
J.3 Competition in the Pharmacy Sector
J.4 Competition in Drug Distribution
K. FORECAST: PHARMACEUTICAL & HEALTHCARE INDUSTRY IN RUSSIA
K.1 Outlook of the Russian Pharmaceutical Industry
K.2 Outlook of the Russian Healthcare Industry
K.3 Outlook for Prescription Drugs Sector
K.4 Outlook for Patented Drugs Market
K.5 Outlook for OTC Medicine Market
K.6 Outlook for the Generic Drugs Market
L. MAJOR DOMESTIC & MULTINATIONAL PLAYERS
L.1 Pharmstandard OJSC
##L.1.1 Corporate Analysis
##L.1.2 Business Segment Analysis
##L.1.3 Financial Analysis
##L.1.4 SWOT Analysis
L.2 Veropharm
##L.2.1 Corporate Analysis
##L.2.2 Business Segment Analysis
##L.2.3 Financial Analysis
##L.2.4 SWOT Analysis
L.3 AbbVie
##L.3.1 Corporate Analysis
##L.3.2 Business Segment Analysis
##L.3.3 Financial Analysis
##L.3.4 SWOT Analysis
L.4 AstraZeneca
##L.4.1 Corporate Analysis
##L.4.2 Business Segment Analysis
##L.4.3 Financial Analysis
##L.4.4 SWOT Analysis
L.5 GlaxoSmithKline
##L.5.1 Corporate Analysis
##L.5.2 Business Segment Analysis
##L.5.3 Financial Analysis
##L.5.4 SWOT Analysis
L.6 Johnson & Johnson
##L.6.1 Corporate Analysis
##L.6.2 Business Segment Analysis
##L.6.3 Financial Analysis
##L.6.4 SWOT Analysis
L.7 Merck & Co.
##L.7.1 Corporate Analysis
##L.7.2 Business Segment Analysis
##L.7.3 Financial Analysis
##L.7.4 SWOT Analysis
L.8 Novartis
##L.8.1 Corporate Analysis
##L.8.2 Business Segment Analysis
##L.8.3 Financial Analysis
##L.8.4 SWOT Analysis
L.9 Pfizer
##L.9.1 Corporate Analysis
##L.9.2 Business Segment Analysis
##L.9.3 Financial Analysis
##L.9.4 SWOT Analysis
L.10 Sanofi SA
##L.10.1 Corporate Analysis
##L.10.2 Business Segment Analysis
##L.10.3 Financial Analysis
##L.10.4 SWOT Analysis
L.11 Takeda Pharmaceutical
##L.11.1 Corporate Analysis
##L.11.2 Business Segment Analysis
##L.11.3 Financial Analysis
##L.11.4 SWOT Analysis
L.12 Biocad
L.13 Pharmsynthez
L.14 R-Pharm
M. GLOSSARY OF TERMS
N. RESEARCH METHODOLOGY
O. DISCLAIMER
LIST OF FIGURES
Figure 1: Growth of the Pharmaceutical Sales in Russia, 2016-2030
Figure 2: Clinical Trial Registrations in Russia, 2015-2019
Figure 3: Porter's Five Forces Analysis of the Russian Pharmaceutical Industry
Figure 4: Bargaining Power of Buyers in the Russian Pharmaceutical Industry
Figure 5: Bargaining Power of Suppliers in the Russian Pharmaceutical Industry
Figure 6: Competitive Rivalry in the Russian Pharmaceutical Industry
Figure 7: Threat of New Entrants to the Russian Pharmaceutical Industry
Figure 8: Threat of Substitutes to the Russian Pharmaceutical Industry
Figure 9: Legislation Challenges that Prevent Foreign Investment in the Russian Pharmaceutical & Healthcare Sector
Figure 10: Import-Export of Pharmaceuticals in Russia (in RUB Million), 2016-2025
Figure 11: Expenditure on Healthcare in Russia, 2016-2030
Figure 12: Forecast of the Prescription Drug Market in Russia, 2016-2030
Figure 13: Forecast of the Patented Drugs Sector in Russia, 2016-2030
Figure 14: Forecast of the OTC Medicine Market in Russia, 2016-2030
Figure 15: Forecast of the Generic Drug Market in Russia, 2016-2030
Figure 1: Growth of the Pharmaceutical Sales in Russia, 2016-2030
Figure 2: Clinical Trial Registrations in Russia, 2015-2019
Figure 3: Porter's Five Forces Analysis of the Russian Pharmaceutical Industry
Figure 4: Bargaining Power of Buyers in the Russian Pharmaceutical Industry
Figure 5: Bargaining Power of Suppliers in the Russian Pharmaceutical Industry
Figure 6: Competitive Rivalry in the Russian Pharmaceutical Industry
Figure 7: Threat of New Entrants to the Russian Pharmaceutical Industry
Figure 8: Threat of Substitutes to the Russian Pharmaceutical Industry
Figure 9: Legislation Challenges that Prevent Foreign Investment in the Russian Pharmaceutical & Healthcare Sector
Figure 10: Import-Export of Pharmaceuticals in Russia (in RUB Million), 2016-2025
Figure 11: Expenditure on Healthcare in Russia, 2016-2030
Figure 12: Forecast of the Prescription Drug Market in Russia, 2016-2030
Figure 13: Forecast of the Patented Drugs Sector in Russia, 2016-2030
Figure 14: Forecast of the OTC Medicine Market in Russia, 2016-2030
Figure 15: Forecast of the Generic Drug Market in Russia, 2016-2030
LIST OF TABLES
Table 1: Growth of the Pharmaceutical Sales in the US, 2017-2025
Table 2: Healthcare Resources in Russia, 2015-2020
Table 3: Inpatient/Outpatient Statistics in Russia, 2015-2020
Table 4: Personnel Employed in the Healthcare Sector in Russia, 2015-2020
Table 5: Import-Export of Pharmaceuticals in Russia (in RUB Million), 2019-2025
Table 6: Import-Export of Pharmaceuticals in Russia (in USD Million), 2019-2025
Table 7: Statistics of the US Pharmaceutical & Healthcare Industry in the US, 2019-2025
Table 8: Expenditure on Healthcare in the US, 2017-2025
Table 9: Government Expenditure on Healthcare in Russia, 2017-2025
Table 10: Healthcare Expenditure by Private Sector on Healthcare in Russia, 2017-2025
Table 11: Forecast of the Prescription Drug Market in Russia, 2017-2025
Table 12: Forecast of the Patented Drugs Sector in Russia, 2017-2025
Table 13: Forecast of the OTC Medicine Market in Russia, 2016-2030
Table 14: Forecast of the Generic Drug Market in Russia, 2017-2025
Table 1: Growth of the Pharmaceutical Sales in the US, 2017-2025
Table 2: Healthcare Resources in Russia, 2015-2020
Table 3: Inpatient/Outpatient Statistics in Russia, 2015-2020
Table 4: Personnel Employed in the Healthcare Sector in Russia, 2015-2020
Table 5: Import-Export of Pharmaceuticals in Russia (in RUB Million), 2019-2025
Table 6: Import-Export of Pharmaceuticals in Russia (in USD Million), 2019-2025
Table 7: Statistics of the US Pharmaceutical & Healthcare Industry in the US, 2019-2025
Table 8: Expenditure on Healthcare in the US, 2017-2025
Table 9: Government Expenditure on Healthcare in Russia, 2017-2025
Table 10: Healthcare Expenditure by Private Sector on Healthcare in Russia, 2017-2025
Table 11: Forecast of the Prescription Drug Market in Russia, 2017-2025
Table 12: Forecast of the Patented Drugs Sector in Russia, 2017-2025
Table 13: Forecast of the OTC Medicine Market in Russia, 2016-2030
Table 14: Forecast of the Generic Drug Market in Russia, 2017-2025
